PL4183778T3 - Przeciwbólowa i przeciwświądowa kompozycja farmaceutyczna oraz sposób jej stosowania - Google Patents
Przeciwbólowa i przeciwświądowa kompozycja farmaceutyczna oraz sposób jej stosowaniaInfo
- Publication number
- PL4183778T3 PL4183778T3 PL21857112.3T PL21857112T PL4183778T3 PL 4183778 T3 PL4183778 T3 PL 4183778T3 PL 21857112 T PL21857112 T PL 21857112T PL 4183778 T3 PL4183778 T3 PL 4183778T3
- Authority
- PL
- Poland
- Prior art keywords
- antipritic
- analgesic
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010845095.2A CN114073698B (zh) | 2020-08-20 | 2020-08-20 | 一种止痛止痒药物组合物及其应用方法 |
| PCT/CN2021/072071 WO2022037006A1 (zh) | 2020-08-20 | 2021-01-15 | 一种止痛止痒药物组合物及其应用方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4183778T3 true PL4183778T3 (pl) | 2025-11-24 |
Family
ID=80282107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21857112.3T PL4183778T3 (pl) | 2020-08-20 | 2021-01-15 | Przeciwbólowa i przeciwświądowa kompozycja farmaceutyczna oraz sposób jej stosowania |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11938118B2 (pl) |
| EP (1) | EP4183778B1 (pl) |
| JP (1) | JP7549405B2 (pl) |
| KR (1) | KR102927058B1 (pl) |
| CN (1) | CN114073698B (pl) |
| AU (1) | AU2021329457B2 (pl) |
| CA (1) | CA3190205C (pl) |
| ES (1) | ES3041707T3 (pl) |
| HR (1) | HRP20251250T1 (pl) |
| HU (1) | HUE073131T2 (pl) |
| PL (1) | PL4183778T3 (pl) |
| RS (1) | RS67282B1 (pl) |
| SM (1) | SMT202500349T1 (pl) |
| WO (1) | WO2022037006A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026006182A1 (en) * | 2024-06-24 | 2026-01-02 | Solu Therapeutics, Inc. | Heterotrifunctional molecules for binding nav1.7 and nav1.8 and methods of treating medical conditions using same |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2747419C (en) | 2009-01-12 | 2014-07-08 | Icagen, Inc. | Sulfonamide derivatives |
| WO2016009303A1 (en) | 2014-07-17 | 2016-01-21 | Pfizer Inc. | Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors |
| US11221329B2 (en) * | 2015-10-30 | 2022-01-11 | Lieber Institute, Inc. | Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity |
| WO2018235851A1 (en) | 2017-06-20 | 2018-12-27 | Raqualia Pharma Inc. | AMIDE DERIVATIVES AS Nav1.7 and Nav1.8 BLOCKERS |
-
2020
- 2020-08-20 CN CN202010845095.2A patent/CN114073698B/zh active Active
-
2021
- 2021-01-15 PL PL21857112.3T patent/PL4183778T3/pl unknown
- 2021-01-15 RS RS20251002A patent/RS67282B1/sr unknown
- 2021-01-15 SM SM20250349T patent/SMT202500349T1/it unknown
- 2021-01-15 JP JP2023511574A patent/JP7549405B2/ja active Active
- 2021-01-15 KR KR1020237006788A patent/KR102927058B1/ko active Active
- 2021-01-15 ES ES21857112T patent/ES3041707T3/es active Active
- 2021-01-15 WO PCT/CN2021/072071 patent/WO2022037006A1/zh not_active Ceased
- 2021-01-15 AU AU2021329457A patent/AU2021329457B2/en active Active
- 2021-01-15 CA CA3190205A patent/CA3190205C/en active Active
- 2021-01-15 EP EP21857112.3A patent/EP4183778B1/en active Active
- 2021-01-15 HR HRP20251250TT patent/HRP20251250T1/hr unknown
- 2021-01-15 HU HUE21857112A patent/HUE073131T2/hu unknown
-
2023
- 2023-02-20 US US18/171,431 patent/US11938118B2/en active Active
-
2024
- 2024-02-28 US US18/590,910 patent/US12318369B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20251250T1 (hr) | 2025-12-19 |
| SMT202500349T1 (it) | 2025-11-10 |
| US20230201170A1 (en) | 2023-06-29 |
| CA3190205C (en) | 2024-11-19 |
| AU2021329457B2 (en) | 2023-08-03 |
| US11938118B2 (en) | 2024-03-26 |
| EP4183778C0 (en) | 2025-07-16 |
| US20240197690A1 (en) | 2024-06-20 |
| CN114073698B (zh) | 2023-03-31 |
| EP4183778A1 (en) | 2023-05-24 |
| RS67282B1 (sr) | 2025-11-28 |
| CN114073698A (zh) | 2022-02-22 |
| JP2023542276A (ja) | 2023-10-06 |
| KR20230047412A (ko) | 2023-04-07 |
| EP4183778A4 (en) | 2024-08-07 |
| HUE073131T2 (hu) | 2025-12-28 |
| WO2022037006A1 (zh) | 2022-02-24 |
| EP4183778B1 (en) | 2025-07-16 |
| ES3041707T3 (en) | 2025-11-13 |
| US12318369B2 (en) | 2025-06-03 |
| AU2021329457A1 (en) | 2023-03-30 |
| CA3190205A1 (en) | 2022-02-24 |
| KR102927058B1 (ko) | 2026-02-12 |
| JP7549405B2 (ja) | 2024-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53388A (fr) | Inhibiteurs d'inflammasome nlrp3 | |
| DK4037666T3 (da) | Forbedring af anordninger og fremgangsmåder til indgivelse af substanser til dyr | |
| IL287751A (en) | Kcnt1 inhibitors and methods of use | |
| IL287768A (en) | Kcnt1 inhibitors and methods of use | |
| DK4267105T3 (da) | Antistofsammensætninger og fremgangsmåder til anvendelse deraf | |
| HRP20251592T1 (hr) | Inhibitori arginaze i metode njihove primjene | |
| MA55893A (fr) | Procédés d'administration de certains inhibiteurs de vmat2 | |
| IL299700A (en) | Kcnt1 inhibitors and methods of use | |
| EP3915538A4 (en) | INJECTION COMPOSITION CONTAINING A FAB I INHIBITOR, AND METHOD OF PREPARING IT | |
| IL311331A (en) | Pharmaceutical composition and use thereof | |
| EP3923925A4 (en) | MIXED HYDROCHLORIC ACID COMPOSITIONS OF RACEMIC BETA-HYDROXYBUTYRATE AND METHOD OF USE | |
| EP4360642A4 (en) | PHARMACEUTICAL COMPOSITION OF PCSK9 INHIBITOR AND GLP-1 RECEPTOR AGONIST | |
| IL316049A (en) | Musuntuzumab pharmaceutical preparations and methods of use | |
| EP3981390A4 (en) | LACOSAMIDE PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL PREPARATION THEREOF | |
| IL286485A (en) | Pi4-kinase inhibitors and methods of using the same | |
| IL314952A (en) | Pharmaceutical preparation containing diphenyldiazole history and methods of use | |
| IL314330A (en) | Apol1 inhibitors and methods of use | |
| TWI925948B (zh) | 含聯環的ｔｙｋ２抑制劑化合物、藥物組合物及其用途 | |
| EP4536239A4 (en) | GPCR INHIBITORS AND THEIR USES | |
| IL312874A (en) | Pharmaceutical composition and use thereof | |
| IL309064A (en) | Heteroaryl compounds as inhibitors of tyk2, composition and application thereof | |
| EP4365183A4 (en) | STEROID COMPOUND, PHARMACEUTICAL COMPOSITION AND ASSOCIATED USES | |
| IL313062A (en) | Tablet formulations of rbp4 inhibitors and methods of use | |
| DK4168033T3 (da) | Indgivelse af cebp-beta-antagonist og fremgangsmåder til anvendelse | |
| EP4225278A4 (en) | PHARMACEUTICAL COMPOSITION OF SIGLEC BINDING AGENTS |